申请人:INTERQUIM, S.A.
公开号:US09321726B2
公开(公告)日:2016-04-26
The invention relates to a process for the preparation of Roflumilast by reaction of an activated form of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid with an activating agent selected from (a) carbonyldiimidazole (CDI), (b) 1,1′-carbonyl-di-(1,2,4-triazol) (CDT), (c) 1,1′-carbonyl-bis-(2-methylimidazol), (d), 1′-carbonyl-dipyperidin, (e) N,N′-dicyclohexylcarbodiimide (DCC), (f) N,N′-diisopropylcarbodiimide (DIC), (g) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and a combination of one of the previous (a)-(g) with (h) N-hydroxysuccinimide or (i) N-hydroxyphthalimide, and the subsequent reaction with 3,5-dichloropyridine-4-amine in the presence of an inorganic base. The invention also relates to the synthesis intermediates.
本发明涉及一种制备
罗氟司特的工艺,通过将3-(环丙基甲氧基)-
4-(二氟甲氧基)苯甲酸的活性形式与以下激活剂之一反应:(a)羰基二
咪唑(
CDI)、(b)1,1'-羰基二-(
1,2,4-三唑)(CDT)、(c)1,1'-羰基双-(
2-甲基咪唑)、(d)1'-羰基二
吡啶、(e)
N,N'-二环己基碳二亚胺(
DCC)、(f)
N,N'-二异丙基碳二亚胺(DIC)、(g)1-乙基-3-(3-二甲基
氨基丙基)碳二
亚胺(EDC),以及前述(a)-(g)中的一个与(h)N-羟基琥珀
酰亚胺或(i)N-羟基邻苯二甲
酰亚胺的组合物反应,并在
无机碱的存在下与3,5-二
氯吡啶-4-胺进一步反应。本发明还涉及合成中间体。